Testing laboratory-made immune cells against glioblastoma
Treatments studied
Part of Cancer clinical trials.
This study is testing special immune cells (called CAR-T cells) in the laboratory to see if they can attack glioblastoma tumor cells. It's a research study that uses a blood sample to grow and test these cells, and it may help find new ways to treat this type of brain tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of brain tumor called 'de novo glioblastoma' that has not been treated yet
- Your tumor does not have an IDH mutation (a genetic change often checked in the biopsy)
- You must weigh at least 50 kg (about 110 pounds)
- You don't have other cancers, active infections, or conditions that weaken the immune system
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new type of immune cell therapy (cytokine-induced killer cells) for people with glioblastoma, a type of brain cancer. The treatment may boost your immune system to fight the cancer.
This trial tests a vaccine made from your own immune cells to fight glioblastoma, a type of brain cancer. It may help your body attack the cancer more effectively after standard treatments.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial tests a new treatment using engineered immune cells (CAR-NK cells) that target two markers found on glioblastoma tumors. The treatment is given directly into the brain to fight tumors that have come back after standard therapy.
This trial tests a new type of immune cell therapy called CAR-NK cells to treat glioblastoma or high-grade glioma that has come back or gotten worse after standard treatment. The cells are engineered to recognize and attack tumor cells in the brain.
This Phase 1 study tests a personalized immune-cell treatment (CAR-T) made from your own cells to attack a marker called B7-H3 on recurring glioblastoma. It may help shrink or control the tumor, but the main goal is to check safety and how the treatment works.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.